Sign Out
Pharmacology: Doxofylline (7-(1-,3-dioxoln-2-ylmethy) theophylline is a novel methylxanthine bronchodilator characterised by the presence of a dioxolane group in position 7, which differentiates it from theophylline. Doxofylline acts by inhibiting the phosphodiesterase enzymes in central and peripheral tissues. The increases intracellular concentration of cyclic AMP that causes smooth muscle relaxation. Doxofylline has shown more potent and bronchospastic activity and less extra respiratory effects in experimental studies than commonly used xanthine drugs.
Pharmacokinetics: Half life of doxofylline is greater than six hours which allows effective constant plasma levels with thrice daily dose regimen. The therapeutic range of doxofylline is significantly wider with respect to that of theophylline. Serum levels are stable and do not require monitoring.
